You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)附屬與深圳潤置訂立委託代建合同

格隆匯2月5日丨華潤醫藥(03320.HK)發佈公吿,於2024年2月5日,公司非全資附屬公司華潤博雅生物與深圳潤置訂立委託代建合同,據此,華潤博雅生物委託深圳潤置承建華潤博雅生物血液製品智能工廠(一期)的服務,總費用為人民幣29,462,393.54元。

智能工廠(一期)位於中國江西省撫州市撫州高新技術產業開發區。預期智能工廠(一期)建成後將包括一個功能完備的血液製品研發生產基地,建築面積超過5.3萬平方米,施工面積超過10.9萬平方米。現時目標計劃智能工廠(一期)將於2025年底或前後竣工,智能工廠(一期)的生產設施將於2027年第三季度前後投入運營。建造將符合中國及智能工廠(一期)所在地區的適用法律、法規、行業程序及標準以及相關的GMP標準。

智能工廠(一期)的建造複雜且規模龐大。透過委託深圳潤置(於中國開發及管理性質及╱或規模類似的建造項目方面的經驗豐富)根據委託代建合同承接服務,預期集團可利用深圳潤置的專業經驗及實力,有效管理及完成華潤博雅生物智能工廠(一期)的建造,從而預期可提升整體效益,更佳控制智能工廠(一期)的建造成本及質素。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account